Disseminated mycobacterial infections after tumor necrosis factor inhibitor use, revealing inborn errors of immunity. (June 2023)

• Record Type: Journal Article
• Authors: Squire, Jacqueline D.; Libertin, Claudia R.; Powers, Harry; Nelson, Jared; Brumble, Lisa; Laham, Federico R.; Agharahimi, Anahita; Freeman, Alexandra F.; Leiding, Jennifer W.
• Is Part Of: International journal of infectious diseases. Volume 131(2023)
• Page Start: 162
• Page End: 165
• Publication Date: 2023-06
• Subjects: Mycobacteria -- Inborn errors of immunity -- TNF inhibitor -- Infliximab -- Immunodeficiency; TNF Tumor necrosis factor -- NTM nontuberculous mycobacterium -- IEI inborn error of immunity -- MAC Mycobacterium aviumcomplex -- IFN-y interferon-gamma; Communicable diseases -- Periodicals; Communicable Diseases -- Periodicals; Communicable diseases; Periodicals; Electronic journals; 616.9
• DOI: 10.1016/j.ijid.2023.04.007
• Languages: English
• ISSNs: 1201-9712

Abstract

Highlights: Novel cases of disseminated nontuberculous mycobacterium after tumor necrosis factor inhibitor in inborn errors of immunity (IEI). Abnormal presentation of IEI associated with susceptibility to mycobacterial disease. Importance of thorough immune evaluation for IEI in disseminated nontuberculous mycobacterium. Abstract: Tumor necrosis factor-a inhibitors can be associated with increased risk of infections, particularly reactivation of latent tuberculosis or nontuberculous mycobacterium (NTM). However, because disseminated NTM is rare, inborn errors of immunity should be considered. We present three patients with disseminated NTM after tumor necrosis factor-a inhibitor use who were found to have inborn errors of immunity.